Interaction between PPARG Pro12Ala and ADIPOQ G276T concerning cholesterol levels in childhood obesity

International Journal of Pediatric Obesity

Volumn 4, Issue 2, 2009, Pages 119-125

  Johansson, Lovisa E ^a   Danielsson, Pernilla ^b   Norgren, Svante ^b   Marcus, Claude ^b   Ridderstråle, Martin ^a  

^a LUND UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adiponectin; APOE; Children; Cholesterol; Genetics; Obesity; PPARG

Indexed keywords

ADIPONECTIN; ALANINE; APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROLINE; TRIACYLGLYCEROL; CHOLESTEROL; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADOLESCENT; ARTICLE; BODY MASS; CHILD; CHOLESTEROL BLOOD LEVEL; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE INTERACTION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CROSS-SECTIONAL STUDY; GENETIC POLYMORPHISM; GENETICS; HETEROZYGOTE; HOMOZYGOTE; RISK FACTOR;

ADIPONECTIN; ADOLESCENT; ALANINE; BODY MASS INDEX; CHILD; CHOLESTEROL; CROSS-SECTIONAL STUDIES; FEMALE; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INSULIN RESISTANCE; LIPIDS; MALE; OBESITY; POLYMORPHISM, GENETIC; PPAR GAMMA; PROLINE; RISK ASSESSMENT; RISK FACTORS;

EID: 67649132708     PISSN: 17477166     EISSN: 17477174     Source Type: Journal    
DOI: 10.1080/17477160802263194     Document Type: Article

References (39)

1. Hedley A, Ogden CL, Johnson CL, Carol MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among U.S. children, adolescents, and adults, 1999-2002. JAMA. 2004; 291:2847-50.
2. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. New Engl J Med. 2004;350:2362-74.
3. Rankinen T, Zuberi A, Chagnon YC, et al. The human obesity gene map: The 2005 update. Obesity. 2006;14: 529-644.
4. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med. 2004;10:1-7.
5. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPAR Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000;26:76-80.
6. Masud S, Ye S. The SAS Group. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: A meta-analysis. J Med Genet. 2003;40: 773-80.
7. Buzzetti R, Petrone A, Caiazzo AM, et al. PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity in childhood obesity. Pediatr Res. 2005;57:138-40.
8. Iwaki M, Matsuda M, Maeda N, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes. 2003;52:1655-63.
9. Trujillo ME, Scherer PE. Adiponectin - journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005;257:167-75.
10. Menzaghi C, Ercolino T, Di Paola R, et al. A haplotype at the adiponectin locus is associated with obesity and other features of the metabolic syndrome. Diabetes. 2002;51:2306-12.
11. Qi L, Doria A, Manson JE, et al. Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetes. Diabetes. 2006;55:1512-6.
12. Gable DR, Hurel SJ, Humphries SE. Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease. Atherosclerosis. 2006;188:231-44.
13. Bennet AM, Di Angelantonio E, Ye Z, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA. 2007;298:1300-11.
14. Guerra A, Rego C, Castro EM, Seixas S, Rocha J. Influence of apolipoprotein e polymorphism on cardiovascular risk factors in obese children. Ann Nutr Metab. 2003;47:49-54.
15. Parlier G, Thomas G, Bereziat G, Fontaine JL, Girardet JP. Relation of apolipoprotein E polymorphism to lipid metabolism in obese children. Pediatr Res. 1997;41:682-5.
16. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. New Engl J Med. 1998;338:1650-6.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;128: 412-9.
18. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78.
19. Filippi E, Sentinelli F, Romeo S, et al. The adiponectin gene SNP +276G>T associates with early-onset coronary artery disease with lower levels of adiponectin in younger coronary artery disease patients (age ≥50 years). J Mol Med. 2005;83: 711-9.
20. Vasseur F, Helbecque N, Dina C, et al. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet. 2002;11:2607-14.
21. Ridker PM, Cook NR, Cheng S, et al. Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol. 2003;23:859-63.
22. Berthier MT, Houde A, Côté M, et al. Impact of adiponectin gene polymorphisms on plasma lipoprotein and adiponectin concentrations of viscerally obese men. J Lipid Res. 2005;46: 237-44.
23. Cruz M, García-Macedo R, Garcia-Valerio Y, et al. Low adiponectin levels predict type 2 diabetes in Mexican children. Diabetes Care. 2004;27:1451-3.
24. Bacci S, Menzaghi C, Ercolino T, et al. The +276 G/T single nucleotide polymorphism of the adiponectin gene is associated with coronary artery disease in type 2 diabetic patients. Diabetes Care. 2004;27:2015-20.
25. Qi L, Li T, Rimm E, et al. The +276 polymorphism of the APM1 gene, plasma adiponectin concentration, and cardiovascular risk in diabetic men. Diabetes. 2005;54:1607-10.
26. Ghoussaini M, Meyre D, Lobbens S, et al. Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population. BMC Med Genet. 2005;6:11.
27. Kamel AF, Norgren S, Strigard K, et al. Age-dependent regulation of lipogenesis in human and rat adipocytes. J Clin Endo Metab. 2004;89:4601-6.
28. Kamel A, Norgren S, Ehrén H, Hildingsson, Marcus C. Antilipolytic effect of insulin and insulin receptor messenger RNA expression in adipocytes of infants, children, and adults. Pediatr Res. 1997;41:563-7.
29. Utermann G, Hees M, Steinmetz A. Polymorphism of apolipoprotein E and occurance of dysbetalipoproteinaemia in man. Nature. 1977;269:604-7.
30. Dallongville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apoE phenotype: A metaanalysis. J Lipid Res. 1992;33:447-54.
31. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20:284-7.
32. Takata N, Awata T, Inukai K, et al. Pro12Ala substitution in peroxisome proliferator-activated receptor gamma 2 is associated with low adiponectin concentrations in young Japanese men. Metabolism. 2004;53:1548-51.
33. Yamamoto Y, Hirose H, Miyashita K, et al. PPAR(gamma)2 gene Pro12Ala polymorphism may influence serum level of an adipocyte-derived protein, adiponectin, in the Japanese population. Metabolism. 2002;51:1407-9.
34. Mousavinasab F, Tahtinen T, Jokelainen J, et al. Effect of the Pro12Ala polymorphism of the PPARg2 gene on serum adiponectin changes. Endocrine. 2005;27:307-9.
35. Mousavinasab F, Tahtinen T, Jokelainen J, et al. Common polymorphisms in the PPARgamma2 and IRS-1 genes and their interaction influence serum adiponectin concentration in young Finnish men. Mol Genet Metab. 2005;84:344-8.
36. Orio F Jr, Palomba S, Cascella T, et al. Lack of an association between peroxisome proliferator-activated receptor-gamma gene Pro12Ala polymorphism and adiponectin levels in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2004; 89:5110-5.
37. Bouatia-Naji N, Meyre D, Lobbens S, et al. ACDC/adiponectin polymorphisms are associated with severe childhood and adult obesity. Diabetes. 2006;55:545-50.
38. Petrone A, Zavarella S, Caiazzo A, et al. The promoter region of the adiponectin gene is a determinant in modulating insulin sensitivity in childhood obesity. Obesity. 2006;14: 1498-504.
39. Williams CL, Hayman LL, Daniels SR, et al. Cardiovascular health in childhood: A statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2002;106:143-60.